Abstract
The study aims at establishing a novel vaccine procedure, using bone marrow-derived DCs that have ingested apoptotic B16 melanoma (DCs(+)), alone or in combination with splenic T lymphocytes from a syngenic donor. Co-immunization with DCs(+) and T cells showed the highest antitumor potential against preestablished B16 tumor in mice, in which CTL and NK cytotoxicities were drastically elevated, while either DCs(+) alone, naive DCs (DCs(-)) alone, or a mixture of DCs(-) and T cells induced less significant therapeutic outcomes. Use of extracellular matrix proteins elevated antitumor activity of DC(-)/T cell vaccine. Compared with the CD8(+) cells, the CD4(+)T cells more remarkably improved the efficacy of DC-based immunotherapy. The present system may be a feasible therapeutic modality to eradicate malignancies including melanoma.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, Neoplasm / immunology*
-
Antimetabolites, Antineoplastic
-
Apoptosis
-
CD4-Positive T-Lymphocytes / immunology
-
CD4-Positive T-Lymphocytes / transplantation
-
CD8-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / transplantation
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use*
-
Cell Line, Tumor
-
Dendritic Cells / immunology
-
Dendritic Cells / transplantation*
-
Extracellular Matrix Proteins / immunology
-
Female
-
Immunotherapy, Adoptive* / methods
-
Killer Cells, Natural / immunology
-
Melanoma, Experimental / immunology
-
Melanoma, Experimental / pathology
-
Melanoma, Experimental / therapy*
-
Mice
-
Mice, Inbred C57BL
-
Puromycin
-
T-Lymphocytes / immunology
-
T-Lymphocytes / transplantation*
-
T-Lymphocytes, Cytotoxic / immunology
-
Transplantation, Isogeneic
Substances
-
Antigens, Neoplasm
-
Antimetabolites, Antineoplastic
-
Cancer Vaccines
-
Extracellular Matrix Proteins
-
Puromycin